|
Match
|
Document |
Document Title |
|
|
US20120141590 |
Technology for the Preparation of Microparticles
Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful... |
|
|
US20080032336 |
Chemokine receptor materials and methods
The present invention provides polynucleotides that encode the chemokine receptors 88-2B or 88C and materials and methods for the recombinant production of these two chemokine receptors. Also... |
|
|
US20170066812 |
INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases. |
|
|
US20160158367 |
CLATHRIN THERAPEUTIC FOR NEUROLOGICAL DISEASES
The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from... |
|
|
US20160158366 |
CLATHRIN THERAPEUTIC FOR AUTOIMMUNE DISEASES
The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from... |
|
|
US20160143992 |
CLATHRIN THERAPEUTIC FOR PSYCHIATRIC and NEUROPSYCHIATRIC DISORDERS
The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from... |
|
|
US20160089448 |
POLYMERIC PRODRUG WITH A SELF-IMMOLATIVE LINKER
A cascade carrier linked prodrug is described comprising a biologically active moiety and a masking group having at least one nucleophile and being distinct from the carrier. |
|
|
US20160060309 |
ISOLATED CLATHRIN THERAPEUTICS
The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from... |
|
|
US20160060297 |
COMPSTATIN AND ANALOGS THEREOF FOR EYE DISORDERS
The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and/or preventing age related macular degeneration and other conditions involving... |
|
|
US20150291562 |
IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE
The description relates to imide-based compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a... |
|
|
US20150150152 |
Chimeric Retinoid X Receptors and Their Use in a Novel Ecdysone Receptor-Based Inducible Gene Expression System
This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a... |
|
|
US20140341892 |
ANTI-ALPHA2 INTEGRIN ANTIBODIES AND THEIR USES
The invention relates to anti-α2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of α2 integrin and inhibit the interaction of α2β1 integrin with... |
|
|
US20140220636 |
PHAGE &phgr MRU POLYNUCLEOTIDES AND POLYPEPTIDES AND USES THEREOF
The invention encompasses phage φmru including phage induction, phage particles, and the phage genome. Also encompassed are phage polypeptides, as well as polynucleotides which encode these... |
|
|
US20140186350 |
COMPOSITIONS AND METHODS FOR LONG ACTING MOLECULES
The invention relates, in part, to compositions and methods that utilize a peptide tag that binds to hemagglutanin (HA). The HA tag can be linked to a molecule such as a protein or nucleic acid... |
|
|
US20140163204 |
DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS
The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active... |
|
|
US20140128575 |
PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES
The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention... |
|
|
US20140080736 |
TUMOUR MARKER PROTEINS AND USES THEREOF
Tumour marker proteins and their preparation from fluids from one or more cancer patients, wherein said fluids are those which collect in a body cavity or space which is naturally occurring or... |
|
|
US20140050739 |
LOCAL COMPLEMENT INHIBITION FOR TREATMENT OF COMPLEMENT-MEDIATED DISORDERS
The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation... |
|
|
US20130288970 |
COMPOSITIONS AND METHODS FOR THE DELIVERY OF OXYGEN
H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H-NOX proteins comprise mutations that impart altered O2 or... |
|
|
US20130232588 |
Chimeric Retinoid X Receptors and Their Use in a Novel Ecdysone Receptor-Based Inducible Gene Expression System
This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a... |
|
|
US20130177569 |
NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 202P5A5 USEFUL IN TREATMENT AND DETECTION OF CANCER
A novel gene 202P5A5 and its encoded protein, and variants thereof, are described wherein 202P5A5 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the... |
|
|
US20130171157 |
NOGO Receptor-Mediated Blockade of Axonal Growth
Disclosed are NgR proteins and biologically active Nogo (ligand) protein fragments. Also disclosed are compositions and methods for modulating the expression or activity of the Nogo and NgR... |
|
|
US20130129740 |
NUCLEIC ACIDS AND PROTEINS FROM STREPTOCOCCUS GROUPS A AND B
The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding... |
|
|
US20130116167 |
ANTI-MART-1 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE
The invention provides a chimeric T cell receptor (TCR) comprising a variable region of a human TCR and a constant region comprising at least an extracellular domain of a constant region of a... |
|
|
US20130052159 |
METHODS FOR TREATMENT OF MICROBIAL DISORDERS
The present invention relates to compositions and methods for treatment of microbial disorder by modulation of the host immune response. More particularly, the present invention relates to... |
|
|
US20120308595 |
Novel Immunogenic Compositions For The Prevention And Treatment of Meningococcal Disease
The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic... |
|
|
US20120277162 |
POLYPEPTIDE COMPOUNDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH
In certain embodiments, this present invention provides polypeptide compositions, including compositions containing a modified polypeptide, and methods for inhibiting Ephrin B2 or EphB4 activity.... |
|
|
US20120270230 |
MUTANT G-PROTEIN COUPLED RECEPTORS AND METHODS FOR SELECTING THEM
The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein... |
|
|
US20120244174 |
TREATMENT OF TAUOPATHIES
The invention is directed to methods of treatment of Alzheimer's disease and other tauopathies, via the administration of antibodies having specificity to abnormal forms of tau protein, the... |
|
|
US20120237449 |
METHODS FOR TREATING NEURAL CELL SWELLING
A composition comprising a novel Ca2+-activated, [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different... |
|
|
US20120156236 |
NEISSERIA MENINGITIDIS ANTIGENS AND COMPOSITIONS
The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for... |
|
|
US20120121601 |
MAMMALIAN RECEPTOR PROTEINS; RELATED REAGENTS AND METHODS
Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the... |
|
|
US20120014952 |
COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS
Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that... |
|
|
US20110177058 |
METHODS AND COMPOSITIONS FOR MODULATING HGF/MET
The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF β chain to c-met. |
|
|
US20110086064 |
COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS OF ALIMENTARY CANAL ORIGIN
Screening and diagnostic reagents, kits and methods for metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of... |
|
|
US20110076234 |
PEPTIDES COMPRISING AN ISODGR MOTIF
Disclosed herein are peptides which include an isoDGR motif and which selectively inhibit αvβ3 integrin. In some embodiments, the isoDGR motif results from the deamidation of an NGR motif. |
|
|
US20110033839 |
Methods of Detecting Signatures of Disease or Conditions in Bodily Fluids
Methods and compositions for diagnosing the presence of a cancer cell in an individual are provided. Methods and compositions for identifying a tumor-specific signature in an individual having... |
|
|
US20110008357 |
ANTIBODIES THAT BIND IL-18 AND METHODS OF INHIBITING IL-18 ACTIVITY
Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies,... |
|
|
US20100322925 |
ALK7 AND MYOSTATIN INHIBITORS AND USES THEREOF
The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is... |
|
|
US20100281572 |
NEMATODE RESISTANT TRANSGENIC PLANTS
Compositions and methods for providing nematode resistance are provided. One aspect provides transgenic plants or cells comprising an inhibitory nucleic acid specific for one or more nematode... |
|
|
US20100240873 |
LIGAND (ACT-4-L) TO A RECEPTOR ON THE SURFACE OF ACTIVATED CD4+ TCELLS
The invention provides ligands and fragments thereof to a receptor on the surface of activated CD4+ T-cells. An exemplary ligand is designated ACT-4-L-h-1. Preferred fragments include purified... |
|
|
US20100234293 |
Novel Neurotrophic Factors
The invention relates to neublastinneurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as... |
|
|
US20100233186 |
NOVEL RECEPTOR THAT BINDS CTLA-8
Isolated receptors for CTLA-8, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to inhibit an immune response. |
|
|
US20100209346 |
AMYLOID BETA(1-42) OLIGOMERS, DERIVATIVES THEREOF AND ANTIBODIES THERETO, METHODS OF PREPARATION THEREOF AND USE THEREOF
The invention relates to neuromodulatory oligomers of the amyloid β(1-42) protein, a particular production method, by means of which the oligomer can be obtained in a reproducible manner at high... |
|
|
US20100196410 |
Streptococcus pneumoniae Antigens and Vaccines
The present invention relates to novel vaccines for the prevention or attenuation of infection by Streptococcus pneumoniae. The invention further relates to isolated nucleic acid molecules... |
|
|
US20100055101 |
CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS
Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors... |
|
|
US20090304719 |
ACTIVATABLE BINDING POLYPEPTIDES AND METHODS OF IDENTIFICATION AND USE THEREOF
The present disclosure provides activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM). The present disclosure... |
|
|
US20090258013 |
NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES
The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases. |
|
|
US20090202475 |
Compositions and methods for treatment of microbial disorders
The present invention relates to compositions and methods for treatment of microbial disorder by modulation of the host immune response. More particularly, the present invention relates to... |
|
|
US20090175850 |
NOGO Receptor Homologs
The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encoding NgR protein homologs in humans and mice. The... |